The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus
Language English Country Ireland Media print-electronic
Document type Journal Article, Observational Study
PubMed
27388675
DOI
10.1016/j.diabres.2016.06.020
PII: S0168-8227(16)30170-X
Knihovny.cz E-resources
- Keywords
- Diabetes mellitus type 2, Dipeptidyl peptidase 4 inhibition, Gliptins, Immune cells,
- MeSH
- Diabetes Mellitus, Type 2 blood drug therapy immunology MeSH
- Adult MeSH
- Dipeptidyl-Peptidase IV Inhibitors administration & dosage MeSH
- Humans MeSH
- Lymphocyte Count MeSH
- T-Lymphocytes, Regulatory drug effects immunology MeSH
- Sitagliptin Phosphate administration & dosage MeSH
- Th1 Cells drug effects immunology MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Names of Substances
- Dipeptidyl-Peptidase IV Inhibitors MeSH
- Sitagliptin Phosphate MeSH
AIM: To assess intraindividually the effects of DPP-IV inhibition on the subpopulations of immune cells in type 2 diabetes mellitus (DM2) patients during the course of treatment with sitagliptin. METHODS: In this open label non-randomized observational study with a control group DM2 patients were examined before the initiation of the DPP-IV inhibitor administration (sitagliptin 100mg once daily) and then after 4weeks and 12months. Inhibition of the blood plasma DPP-IV enzymatic activity was determined by a chromogenic assay, the immunophenotyping of the blood cell subpopulations was performed using flow cytometry and blood plasma cytokine concentrations were quantified using an array-based multiplex ELISA. All parameters were evaluated in relation to the entry values in individual patients. RESULTS: The blood plasma DPP-IV enzymatic activity was effectively inhibited during the sitagliptin treatment. A significant decrease of the proportion of Treg cells (to 86±31% (median±SD) of entry values, p=0.001) and an increase of Th1 cells (to 120±103% (median±SD) of entry values, p=0.004) were observed after 4weeks but not after one year of the sitagliptin treatment. No changes were observed in the ratio of CD4(+)/CD8(+) cells, in the quantity of NK and Th2 cells and blood plasma cytokine levels. CONCLUSIONS: Sitagliptin treatment may cause temporary changes of the proportion of lymphocyte subpopulations in patients with DM2. The consequent deregulation of the immune system should be considered as a possible cause of the eventual side effects of long term DPP-IV inhibition.
References provided by Crossref.org
